Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus (SLE)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator |
| |
| Abatacept, 30 mg/kg | Active Comparator |
| |
| Abatacept, 10 mg/kg | Other | Open-label long-term extension phase |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Drug | Infusion, Intravenous, single dose, Day 1 |
| |
| Abatacept |
| Measure | Description | Time Frame |
|---|---|---|
| Short-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs | AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. | From Day 1 of double-blind period to 1st dose of long-term period |
| Short-term Period: Number of Adverse Events (AEs) Related to Study Drug | AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. Intensity = mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening/disabling (grade 4). | From Day 1 of double-blind period to 1st dose of long-term period |
| Short-term Period: MeanSystolic and Diastolic Blood Pressure | Vital sign measurements are summarized without regard to position (sitting, standing, supine). | Day 1 predose and postdose and Day 2 |
| Short-term Period: Mean Heart Rate | Vital signs measurements are summarized without regard to position (sitting, standing, supine). | Day 1 predose and postdose and Day 2 |
| Short-term Period: Mean Respirations Rate | Vital sign measurements are summarized without regard to position (sitting, standing, supine). |
| Measure | Description | Time Frame |
|---|---|---|
| Long-term Period: Number of Participants With Death as Outcome, Serious AEs (SAEs), Discontinuations Due to AEs, and Treatment-related AEs | AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Shanghai | Shanghai Municipality | 200001 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 11678454 | Background | Liu MF, Wang CR, Lin LC, Wu CR. CTLA-4 gene polymorphism in promoter and exon-1 regions in Chinese patients with systemic lupus erythematosus. Lupus. 2001;10(9):647-9. doi: 10.1191/096120301682430249. |
Not provided
Not provided
Thirteen (13) participants were enrolled in the short-term period of the study. Four (4/13, 30.8%) of these participants were not randomized: 3 (23.1%) no longer met study criteria after screening, and 1 (7.7%) withdrew consent. All 9 participants who completed the short-term period entered the long-term period.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Abatacept, 30/10 mg/kg | Short-term period: Participants received a single dose of 30-mg/kg dose of abatacept intravenously (IV) Long-term period: All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study |
| FG001 | Placebo/Abatacept,10 mg/kg | Short-term period: Participants received a single dose of placebo intravenously Long-term period: Placebo arm discontinued. All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Short-term Period |
| |||||||||||||
| Long-term Extension Period |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Abatacept (30 mg/kg) | Infusion, Intravenous, 30 mg/kg, single dose, 24 hours |
| BG001 | Placebo | Infusion, Intravenous, single dose, 24 hours |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Short-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs | AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. | All participants who received at least 1 dose of study medication. | Posted | Number | Participants | From Day 1 of double-blind period to 1st dose of long-term period |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Abatacept 30 mg/kg |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| DIZZINESS | Nervous system disorders | MedDRA 11.1 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| BMS Study Director | Bristol-Myers Squibb | Clinical.Trials@bms.com |
Not provided
| ID | Term |
|---|---|
| D008181 | Lupus Nephritis |
| ID | Term |
|---|---|
| D005921 | Glomerulonephritis |
| D009393 | Nephritis |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069594 | Abatacept |
| ID | Term |
|---|---|
| D018796 | Immunoconjugates |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D012712 | Serum Globulins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Infusion, Intravenous, 30mg/kg, single dose, Day 1 |
|
|
| Abatacept | Drug | Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study |
|
|
| Day 1 predose and postdose and Day 2 |
| Short-term Period: Mean Temperature | Vital sign measurements are summarized without regard to position (sitting, standing, supine). | Day 1 predose and postdose and Day 2 |
| Short-term Period: Number of Participants With Clinical Laboratory and Electrocardiogram (ECG) Abnormalities | Laboratory tests consisted of complete blood count, chemistry, and urinalysis. | Screening and Days 1 and 2 |
| Days 15 to 56 days post last dose of the long-term period |
| Minimum (Cmin) Plasma Concentration of Abatacept | Cmin is the minimum, or trough, concentration of a drug observed after its administration and just prior to the administration of a subsequent dose. | Days 15, 29, 85, 169, 253 and 337 |
| Maximum (Cmax) Plasma Concentration of Abatacept | Cmax is a drug's maximum, or peak, concentration observed after its administration. | Postdosing Day 1 |
| Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests | preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. hemoglobin (g/dL): >3g/dL drop from preRX; hematocrit (%): <0.75*preRX; erythrocytes (*10^6 c/uL): <0.75*preRX; platelet count (*10^9 c/L): <0.67*LLN or >1.5*ULN, or <100,000/mm^3 or if preRX<LLN, use <0.5*preRX and <100,000/mm^3; leukocytes (*10^3 c/uL): <0.75*LLN, >1.25*ULN, <0.8*preRX if preRX <LLN or >1.2*preRX if preRX >ULN; >ULN if preRX <LLN, <LLN if >ULN preRX; neutrophils+bands (*10^3 c/uL): if value <1.00*10^3 c/uL; lymphocytes (*10^3 c/uL): if value <0.750*10^3 c/uL or if value >7.50*10^3 c/uL; monocytes (*10^3 c/uL): if value >2000/mm^3; basophils (*10^3 c/uL): if value >400/mm^3; eosinophils (*10^3 c/uL): if value> 0.750*10^3 c/uL | Days 15 to 56 days post last dose of the long-term period |
| Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued) | preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Glucose (mg/dL): <65 or >220. Glucose, fasting(mg/dL): <0.8*LLN or >1.5* ULN; if preRX<LLN, use <0.8*preRX or >ULN; if preRX>ULN, use >2.0*preRX or <LLN. Protein, total (g/dL): <0.9*LLN or >1.1*ULN; if preRX<LLN, use 0.9*preRX or >ULN if preRX >ULN, use 1.1*preRX or <LLN. Albumin (g/dL): <0.9*LLN, or if preRX<LLN use <0.75*preRX. Uric acid (mg/dL): >1.5*ULN; if preRX>ULN use >2*preRX. Protein, urine: if missing preRX, use>=2; if >=4; if preRX=0 or 0.5, use >=2; if preRX=1, use >=3, or if preRX=2 or 3, use >= 4. Glucose, urine: if preRX missing, use >=2; if >=4, or if preRX=0 or 0.5 use >=2,or if preRX=1, use >=3, or if preRX=2 or 3 use >=4. Blood, urine: if preRX missing, use>= 2, or if >=4, or if preRX=0 or 0.5, use >=2, or if preRX=1, use >=3; if preRX=2 or 3 use >=4. WBC, urine (hpf): if missing preRX, use>= 2, or if >= 4, or if preRX =0 or 0.5 use >=2, or if preRX=1 use >=3, or if preRX=2 or 3 use >=4. | Days 15 to 56 days post last dose of the long-term period |
| Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued) | ULN=upper limit of normal; preRX=pretreatment: ALP (U/L): >2*ULN, or if preRX>ULN, use >3*preRX; AST (U/L): >3*ULN, or if preRX>ULN, use >4*preRX; ALT (U/L): >3X*ULN, or if preRX>ULN, use >4*preRX; GGT (/L): >*ULN, or if preRX>ULN, use >3*preRX; bilirubin (mg/dL): >2*ULN, or if preRX>ULN, use >4*preRX; BUN (mg/dL):>2*preRX; sodium: <.95*LLN, >1.05*ULN, <.95* preRX if <LLN preRX, >1.05*preRX if >ULN preRX; >ULN if <LLN preRX, <LLN if >ULN preRX; potassium: chloride: calcium: phosphorous: | Days 15 to 56 days post last dose of the long-term period |
| Long-term Period: Number of Participants With Abatacept-specific Antibodies | Antiabatacept antibodies in human serum were assayed using a validated electrochemiluminescent immunoassay during the period of known analyte stability. | Day15 to 56 days post last dose of the long-term period |
| NOT COMPLETED |
|
|
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Duration of Lupus Nephritis | Mean | Standard Deviation | months |
|
| Duration of Systemic Lupus Erythematosus (SLE) | Mean | Standard Deviation | years |
|
| Weight | Mean | Standard Deviation | kg |
|
Infusion, Intravenous, 30 mg/kg, single dose, 24 hours
| OG001 | Placebo | Infusion, Intravenous, single dose, 24 hours |
|
|
| Secondary | Long-term Period: Number of Participants With Death as Outcome, Serious AEs (SAEs), Discontinuations Due to AEs, and Treatment-related AEs | AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. | All participants who received at least 1 infusion of abatacept during the open-label long-term extension period of the study. | Posted | Number | Participants | Days 15 to 56 days post last dose of the long-term period |
|
|
|
| Secondary | Minimum (Cmin) Plasma Concentration of Abatacept | Cmin is the minimum, or trough, concentration of a drug observed after its administration and just prior to the administration of a subsequent dose. | All participants who received at least 1 dose of study drug and had a serum concentration measurement relative to dosing time. n=number of evaluable participants. | Posted | Mean | Standard Deviation | ug/mL | Days 15, 29, 85, 169, 253 and 337 |
|
|
|
| Primary | Short-term Period: Number of Adverse Events (AEs) Related to Study Drug | AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. Intensity = mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening/disabling (grade 4). | All participants who received at least 1 dose of study medication. | Posted | Number | Events | From Day 1 of double-blind period to 1st dose of long-term period |
|
|
|
| Primary | Short-term Period: MeanSystolic and Diastolic Blood Pressure | Vital sign measurements are summarized without regard to position (sitting, standing, supine). | All participants who received at least 1 dose of study medication. | Posted | Mean | Standard Deviation | mm Hg | Day 1 predose and postdose and Day 2 |
|
|
|
| Primary | Short-term Period: Mean Heart Rate | Vital signs measurements are summarized without regard to position (sitting, standing, supine). | All participants who received at least 1 dose of study medication. | Posted | Mean | Standard Deviation | beats per minute | Day 1 predose and postdose and Day 2 |
|
|
|
| Primary | Short-term Period: Mean Respirations Rate | Vital sign measurements are summarized without regard to position (sitting, standing, supine). | All participants who received at least 1 dose of study medication. | Posted | Mean | Standard Deviation | Respirations per minute | Day 1 predose and postdose and Day 2 |
|
|
|
| Secondary | Maximum (Cmax) Plasma Concentration of Abatacept | Cmax is a drug's maximum, or peak, concentration observed after its administration. | All participants who received at least 1 dose of study drug and had a serum concentration measurement relative to dosing time. n=number of evaluable participants. | Posted | Geometric Mean | Geometric Coefficient of Variation | ug/mL | Postdosing Day 1 |
|
|
|
| Primary | Short-term Period: Mean Temperature | Vital sign measurements are summarized without regard to position (sitting, standing, supine). | All participants who received at least 1 dose of study medication. | Posted | Mean | Standard Deviation | Degrees Celsius | Day 1 predose and postdose and Day 2 |
|
|
|
| Primary | Short-term Period: Number of Participants With Clinical Laboratory and Electrocardiogram (ECG) Abnormalities | Laboratory tests consisted of complete blood count, chemistry, and urinalysis. | All participants who received at least 1 dose of study drug | Posted | Number | Participants | Screening and Days 1 and 2 |
|
|
|
| Secondary | Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests | preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. hemoglobin (g/dL): >3g/dL drop from preRX; hematocrit (%): <0.75*preRX; erythrocytes (*10^6 c/uL): <0.75*preRX; platelet count (*10^9 c/L): <0.67*LLN or >1.5*ULN, or <100,000/mm^3 or if preRX<LLN, use <0.5*preRX and <100,000/mm^3; leukocytes (*10^3 c/uL): <0.75*LLN, >1.25*ULN, <0.8*preRX if preRX <LLN or >1.2*preRX if preRX >ULN; >ULN if preRX <LLN, <LLN if >ULN preRX; neutrophils+bands (*10^3 c/uL): if value <1.00*10^3 c/uL; lymphocytes (*10^3 c/uL): if value <0.750*10^3 c/uL or if value >7.50*10^3 c/uL; monocytes (*10^3 c/uL): if value >2000/mm^3; basophils (*10^3 c/uL): if value >400/mm^3; eosinophils (*10^3 c/uL): if value> 0.750*10^3 c/uL | All participants who received at least 1 dose of study medication. | Posted | Number | Participants | Days 15 to 56 days post last dose of the long-term period |
|
|
|
| Secondary | Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued) | preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Glucose (mg/dL): <65 or >220. Glucose, fasting(mg/dL): <0.8*LLN or >1.5* ULN; if preRX<LLN, use <0.8*preRX or >ULN; if preRX>ULN, use >2.0*preRX or <LLN. Protein, total (g/dL): <0.9*LLN or >1.1*ULN; if preRX<LLN, use 0.9*preRX or >ULN if preRX >ULN, use 1.1*preRX or <LLN. Albumin (g/dL): <0.9*LLN, or if preRX<LLN use <0.75*preRX. Uric acid (mg/dL): >1.5*ULN; if preRX>ULN use >2*preRX. Protein, urine: if missing preRX, use>=2; if >=4; if preRX=0 or 0.5, use >=2; if preRX=1, use >=3, or if preRX=2 or 3, use >= 4. Glucose, urine: if preRX missing, use >=2; if >=4, or if preRX=0 or 0.5 use >=2,or if preRX=1, use >=3, or if preRX=2 or 3 use >=4. Blood, urine: if preRX missing, use>= 2, or if >=4, or if preRX=0 or 0.5, use >=2, or if preRX=1, use >=3; if preRX=2 or 3 use >=4. WBC, urine (hpf): if missing preRX, use>= 2, or if >= 4, or if preRX =0 or 0.5 use >=2, or if preRX=1 use >=3, or if preRX=2 or 3 use >=4. | All participants who received at least 1 dose of study medication. | Posted | Number | Participants | Days 15 to 56 days post last dose of the long-term period |
|
|
|
| Secondary | Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued) | ULN=upper limit of normal; preRX=pretreatment: ALP (U/L): >2*ULN, or if preRX>ULN, use >3*preRX; AST (U/L): >3*ULN, or if preRX>ULN, use >4*preRX; ALT (U/L): >3X*ULN, or if preRX>ULN, use >4*preRX; GGT (/L): >*ULN, or if preRX>ULN, use >3*preRX; bilirubin (mg/dL): >2*ULN, or if preRX>ULN, use >4*preRX; BUN (mg/dL):>2*preRX; sodium: <.95*LLN, >1.05*ULN, <.95* preRX if <LLN preRX, >1.05*preRX if >ULN preRX; >ULN if <LLN preRX, <LLN if >ULN preRX; potassium: chloride: calcium: phosphorous: | All participants who received at least 1 dose of study medication. | Posted | Number | Participants | Days 15 to 56 days post last dose of the long-term period |
|
|
|
| Secondary | Long-term Period: Number of Participants With Abatacept-specific Antibodies | Antiabatacept antibodies in human serum were assayed using a validated electrochemiluminescent immunoassay during the period of known analyte stability. | All participants who received at least 1 dose of abatacept and had an immunogenicity test result. | Posted | Number | Participants | Day15 to 56 days post last dose of the long-term period |
|
|
|
| 0 |
| 6 |
| 3 |
| 6 |
| EG001 | Placebo | 0 | 3 | 1 | 3 |
| VOMITING | Gastrointestinal disorders | MedDRA 11.1 | Systematic Assessment |
|
| DIARRHOEA | Gastrointestinal disorders | MedDRA 11.1 | Systematic Assessment |
|
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA 11.1 | Systematic Assessment |
|
| OROPHARYNGEAL PAIN | Respiratory, thoracic and mediastinal disorders | MedDRA 11.1 | Systematic Assessment |
|
Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.
| D052776 |
| Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D008180 | Lupus Erythematosus, Systemic |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D001798 |
| Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D005916 | Globulins |
| Title | Measurements |
|---|---|
|
| AEs |
|
| Treatment-related AEs |
|
| Title | Measurements |
|---|---|
|
| Day 169 (n=7) |
|
| Day 253 (n=7) |
|
| Day 337 (n=4) |
|
| Diarrhea (mild) |
|
| Diastolic blood pressure: Day 1 predose |
|
| Diastolic blood pressure: Day 1 postdose |
|
| Systolic blood pressure: Day 2 |
|
| Diastolic blood pressure: Day 2 |
|
| Day 2 |
|
| Day 2 |
|
| Day 2 |
|
| Title | Measurements |
|---|---|
|
| Hematocrit (high) |
|
| Erythrocytes (low) |
|
| Erythrocytes (high) |
|
| Platelet count (low or high) |
|
| Leukocytes (low) |
|
| Leukocytes (high) |
|
| Neutrophils +bands (absolute) (low) |
|
| Neutrophils +bands (absolute) (high) |
|
| Absolute lymphocytes (low) |
|
| Absolute lymphocytes (high) |
|
| Absolute monocytes (low) |
|
| Absolute monocytes (high) |
|
| Absolute basophils (low) |
|
| Absolute basophils (high) |
|
| Absolute eosinophils (low) |
|
| Absolute eosinophils (high) |
|
| Title | Measurements |
|---|---|
|
| Glucose, fasting serum (high) |
|
| Protein, total (low) |
|
| Protein, total (high) |
|
| Albumin (low) |
|
| Albumin (high) |
|
| Uric acid (low) |
|
| Uric acid (high) |
|
| Protein, urine (low) |
|
| Protein, urine (high) |
|
| Glucose, urine (low) |
|
| Glucose, urine (high) |
|
| Blood, urine (low) |
|
| Blood, urine (high) |
|
| WBC, urine (low) |
|
| White blood cell (WBC) count, urine (high) |
|
| Title | Measurements |
|---|---|
|
| AST (high) |
|
| Alanine aminotransferase (ALT) (low) |
|
| ALT (high) |
|
| G-glutamyl transferase (GGT) (low) |
|
| GGT (high) |
|
| Bilirubin, total (low) |
|
| Bilirubin, total (high) |
|
| Blood urea nitrogen (BUN) (low) |
|
| BUN (high) |
|
| Sodium, serum (low) |
|
| Sodium, serum (high) |
|
| Potassium, serum (low) |
|
| Potassium, serum (high) |
|
| Chloride, serum (low) |
|
| Chloride, serum (high) |
|
| Calcium, total (low) |
|
| Calcium, total (high) |
|
| Phosphorus, inorganic (low) |
|
| Phosphorus, inorganic (high) |
|